B-Diagnostic_tool	0	3	OCT
I-Diagnostic_tool	4	15	Angiography
O	16	23	Metrics
O	24	31	Predict
O	32	43	Progression
O	44	46	of
B-Disease	47	55	Diabetic
I-Disease	56	67	Retinopathy
O	68	71	and
O	72	83	Development
O	84	86	of
B-Disease	87	95	Diabetic
I-Disease	96	103	Macular
I-Disease	104	109	Edema
O	109	110	:
O	111	112	A
O	113	124	Prospective
O	125	130	Study
O	130	131	.

O	133	135	To
O	136	149	prospectively
O	150	159	determine
O	160	163	the
O	164	176	relationship
O	177	179	of
B-Diagnostic_tool	180	183	OCT
I-Diagnostic_tool	184	195	angiography
O	196	197	(
B-Diagnostic_tool	197	201	OCTA
O	201	202	)
O	203	210	metrics
O	211	213	to
B-Disease	214	222	diabetic
I-Disease	223	234	retinopathy
O	235	236	(
B-Disease	236	238	DR
O	238	239	)
O	240	251	progression
O	252	255	and
O	256	267	development
O	268	270	of
B-Disease	271	279	diabetic
I-Disease	280	287	macular
I-Disease	288	293	edema
O	294	295	(
B-Disease	295	298	DME
O	298	299	)
O	299	300	.

O	301	312	Prospective
O	312	313	,
O	314	327	observational
O	328	333	study
O	333	334	.

O	335	336	A
O	337	342	total
O	343	345	of
O	346	349	205
B-Anatomy	350	354	eyes
O	355	359	from
O	360	363	129
O	364	372	patients
O	373	377	with
B-Disease	378	386	diabetes
I-Disease	387	395	mellitus
O	396	404	followed
O	405	407	up
O	408	411	for
O	412	414	at
O	415	420	least
O	421	422	2
O	423	428	years
O	428	429	.

O	430	433	All
O	434	446	participants
O	447	456	underwent
B-Diagnostic_tool	457	461	OCTA
O	462	466	with
O	467	468	a
B-Diagnostic_tool	469	474	swept
I-Diagnostic_tool	474	475	-
I-Diagnostic_tool	475	481	source
I-Diagnostic_tool	482	485	OCT
I-Diagnostic_tool	486	492	device
O	493	494	(
B-Diagnostic_tool	494	497	DRI
I-Diagnostic_tool	497	498	-
I-Diagnostic_tool	498	501	OCT
I-Diagnostic_tool	502	508	Triton
O	508	509	,
O	510	516	Topcon
O	516	517	,
O	518	521	Inc
O	521	522	,
O	523	528	Tokyo
O	528	529	,
O	530	535	Japan
O	535	536	)
O	536	537	.

O	538	548	Individual
B-Diagnostic_tool	549	553	OCTA
I-Diagnostic_tool	554	560	images
O	561	563	of
B-Anatomy	564	575	superficial
I-Anatomy	576	585	capillary
I-Anatomy	586	592	plexus
O	593	594	(
B-Anatomy	594	597	SCP
O	597	598	)
O	599	602	and
B-Anatomy	603	607	deep
I-Anatomy	608	617	capillary
I-Anatomy	618	624	plexus
O	625	626	(
B-Anatomy	626	629	DCP
O	629	630	)
O	631	635	were
O	636	645	generated
O	646	648	by
O	649	658	IMAGEnet6
O	659	660	(
O	660	665	Basic
O	666	673	License
O	674	676	10
O	676	677	)
O	677	678	.

O	679	684	After
O	685	686	a
O	687	694	quality
O	695	700	check
O	700	701	,
O	702	711	automated
O	712	724	measurements
O	725	727	of
B-Characteristic	728	734	foveal
I-Characteristic	735	744	avascular
I-Characteristic	745	749	zone
I-Characteristic	750	751	(
I-Characteristic	751	754	FAZ
I-Characteristic	754	755	)
I-Characteristic	756	760	area
O	760	761	,
B-Characteristic	762	765	FAZ
I-Characteristic	766	777	circularity
O	777	778	,
B-Characteristic	779	785	vessel
I-Characteristic	786	793	density
O	794	795	(
B-Characteristic	795	797	VD
O	797	798	)
O	798	799	,
O	800	803	and
B-Characteristic	804	811	fractal
I-Characteristic	812	821	dimension
O	822	823	(
B-Characteristic	823	825	FD
O	825	826	)
O	827	829	of
O	830	834	both
B-Anatomy	835	838	SCP
O	839	842	and
B-Anatomy	843	846	DCP
O	847	851	were
O	852	856	then
O	857	865	obtained
O	865	866	.

O	867	878	Progression
O	879	881	of
B-Disease	882	884	DR
O	885	888	and
O	889	900	development
O	901	903	of
B-Disease	904	907	DME
O	907	908	.

O	909	913	Over
O	914	915	a
O	916	922	median
O	923	929	follow
O	929	930	-
O	930	932	up
O	933	935	of
O	936	938	27
O	938	939	.
O	939	941	14
O	942	948	months
O	949	950	(
O	950	963	interquartile
O	964	969	range
O	969	970	,
O	971	973	24
O	973	974	.
O	974	976	16
O	976	977	-
O	977	979	30
O	979	980	.
O	980	982	41
O	983	989	months
O	989	990	)
O	990	991	,
O	992	994	28
O	995	997	of
O	998	1001	the
O	1002	1005	205
B-Anatomy	1006	1010	eyes
O	1011	1012	(
O	1012	1014	13
O	1014	1015	.
O	1015	1017	66
O	1017	1018	%
O	1018	1019	)
O	1020	1029	developed
B-Disease	1030	1032	DR
O	1033	1044	progression
O	1044	1045	.

O	1046	1048	Of
O	1049	1052	the
O	1053	1056	194
B-Anatomy	1057	1061	eyes
O	1062	1069	without
B-Disease	1070	1073	DME
O	1074	1076	at
O	1077	1085	baseline
O	1085	1086	,
O	1087	1089	17
O	1090	1091	(
O	1091	1092	8
O	1092	1093	.
O	1093	1095	76
O	1095	1096	%
O	1096	1097	)
O	1098	1107	developed
B-Disease	1108	1111	DME
O	1111	1112	.

B-Characteristic	1113	1119	Larger
I-Characteristic	1120	1123	FAZ
I-Characteristic	1124	1128	area
O	1129	1130	(
O	1130	1136	hazard
O	1137	1142	ratio
O	1143	1144	[
O	1144	1146	HR
O	1146	1147	]
O	1147	1148	,
O	1149	1150	1
O	1150	1151	.
O	1151	1154	829
O	1155	1158	per
O	1159	1161	SD
O	1162	1170	increase
O	1170	1171	;
O	1172	1174	95
O	1174	1175	%
O	1176	1186	confidence
O	1187	1195	interval
O	1196	1197	[
O	1197	1199	CI
O	1199	1200	]
O	1201	1202	,
O	1203	1204	1
O	1204	1205	.
O	1205	1208	332
O	1208	1209	-
O	1209	1210	2
O	1210	1211	.
O	1211	1214	512
O	1214	1215	)
O	1215	1216	,
B-Characteristic	1217	1222	lower
I-Characteristic	1223	1225	VD
O	1226	1227	(
O	1227	1229	HR
O	1229	1230	,
O	1231	1232	1
O	1232	1233	.
O	1233	1236	908
O	1237	1240	per
O	1241	1243	SD
O	1244	1252	decrease
O	1252	1253	;
O	1254	1256	95
O	1256	1257	%
O	1258	1260	CI
O	1260	1261	,
O	1262	1263	1
O	1263	1264	.
O	1264	1267	303
O	1267	1268	-
O	1268	1269	2
O	1269	1270	.
O	1270	1273	793
O	1273	1274	)
O	1274	1275	,
O	1276	1279	and
B-Characteristic	1280	1285	lower
I-Characteristic	1286	1288	FD
O	1289	1290	(
O	1290	1292	HR
O	1292	1293	,
O	1294	1295	4
O	1295	1296	.
O	1296	1299	464
O	1300	1303	per
O	1304	1306	SD
O	1307	1315	decrease
O	1315	1316	;
O	1317	1319	95
O	1319	1320	%
O	1321	1323	CI
O	1323	1324	,
O	1325	1326	1
O	1326	1327	.
O	1327	1330	337
O	1330	1331	-
O	1331	1333	14
O	1333	1334	.
O	1334	1337	903
O	1337	1338	)
O	1339	1341	of
B-Anatomy	1342	1345	DCP
O	1346	1350	were
O	1351	1364	significantly
O	1365	1375	associated
O	1376	1380	with
B-Disease	1381	1383	DR
O	1384	1395	progression
O	1396	1401	after
O	1402	1411	adjusting
O	1412	1415	for
O	1416	1427	established
O	1428	1432	risk
O	1433	1440	factors
O	1441	1442	(
B-Characteristic	1442	1444	DR
I-Characteristic	1445	1453	severity
O	1453	1454	,
B-Characteristic	1455	1463	glycated
I-Characteristic	1464	1474	hemoglobin
O	1474	1475	,
B-Characteristic	1476	1484	duration
I-Characteristic	1485	1487	of
I-Characteristic	1488	1496	diabetes
O	1496	1497	,
B-Characteristic	1498	1501	age
O	1501	1502	,
O	1503	1506	and
B-Characteristic	1507	1511	mean
I-Characteristic	1512	1520	arterial
I-Characteristic	1521	1526	blood
I-Characteristic	1527	1535	pressure
O	1536	1538	at
O	1539	1547	baseline
O	1547	1548	)
O	1548	1549	.

B-Characteristic	1550	1555	Lower
I-Characteristic	1556	1558	VD
I-Characteristic	1559	1561	of
I-Characteristic	1562	1565	SCP
O	1566	1567	(
O	1567	1569	HR
O	1569	1570	,
O	1571	1572	1
O	1572	1573	.
O	1573	1576	789
O	1577	1580	per
O	1581	1583	SD
O	1584	1592	decrease
O	1592	1593	;
O	1594	1596	95
O	1596	1597	%
O	1598	1600	CI
O	1600	1601	,
O	1602	1603	1
O	1603	1604	.
O	1604	1607	027
O	1607	1608	-
O	1608	1609	4
O	1609	1610	.
O	1610	1613	512
O	1613	1614	)
O	1615	1618	was
O	1619	1629	associated
O	1630	1634	with
B-Disease	1635	1638	DME
O	1639	1650	development
O	1650	1651	.

O	1652	1660	Compared
O	1661	1665	with
O	1666	1669	the
O	1670	1675	model
O	1676	1680	with
O	1681	1692	established
O	1693	1697	risk
O	1698	1705	factors
O	1706	1711	alone
O	1711	1712	,
O	1713	1716	the
O	1717	1725	addition
O	1726	1728	of
B-Diagnostic_tool	1729	1733	OCTA
O	1734	1741	metrics
O	1742	1750	improved
O	1751	1754	the
O	1755	1765	predictive
O	1766	1780	discrimination
O	1781	1783	of
B-Disease	1784	1786	DR
O	1787	1798	progression
O	1799	1800	(
B-Characteristic	1800	1803	FAZ
I-Characteristic	1804	1808	area
I-Characteristic	1809	1811	of
I-Characteristic	1812	1815	DCP
O	1815	1816	,
O	1817	1818	C
O	1818	1819	-
O	1819	1829	statistics
O	1830	1831	0
O	1831	1832	.
O	1832	1835	723
O	1836	1838	vs
O	1838	1839	.
O	1840	1841	0
O	1841	1842	.
O	1842	1845	677
O	1845	1846	,
O	1847	1848	P
O	1850	1851	<
O	1853	1854	0
O	1854	1855	.
O	1855	1858	001
O	1858	1859	;
B-Characteristic	1860	1862	VD
I-Characteristic	1863	1865	of
I-Characteristic	1866	1869	DCP
O	1869	1870	,
O	1871	1872	C
O	1872	1873	-
O	1873	1883	statistics
O	1884	1885	0
O	1885	1886	.
O	1886	1889	727
O	1890	1892	vs
O	1892	1893	.
O	1894	1895	0
O	1895	1896	.
O	1896	1899	677
O	1899	1900	,
O	1901	1902	P
O	1903	1904	=
O	1905	1906	0
O	1906	1907	.
O	1907	1910	001
O	1910	1911	;
B-Characteristic	1912	1914	FD
I-Characteristic	1915	1917	of
I-Characteristic	1918	1921	DCP
O	1921	1922	,
O	1923	1924	C
O	1924	1925	-
O	1925	1935	statistics
O	1936	1937	0
O	1937	1938	.
O	1938	1941	738
O	1942	1944	vs
O	1944	1945	.
O	1946	1947	0
O	1947	1948	.
O	1948	1951	677
O	1951	1952	,
O	1953	1954	P
O	1956	1957	<
O	1959	1960	0
O	1960	1961	.
O	1961	1964	001
O	1964	1965	)
O	1966	1969	and
B-Disease	1970	1973	DME
O	1974	1985	development
O	1986	1987	(
B-Characteristic	1987	1989	VD
I-Characteristic	1990	1992	of
I-Characteristic	1993	1996	SCP
O	1996	1997	,
O	1998	1999	C
O	1999	2000	-
O	2000	2010	statistics
O	2011	2012	0
O	2012	2013	.
O	2013	2016	904
O	2017	2019	vs
O	2019	2020	.
O	2021	2022	0
O	2022	2023	.
O	2023	2026	875
O	2026	2027	,
O	2028	2029	P
O	2030	2031	=
O	2032	2033	0
O	2033	2034	.
O	2034	2037	036
O	2037	2038	)
O	2038	2039	.

O	2040	2043	The
B-Characteristic	2044	2047	FAZ
I-Characteristic	2048	2052	area
O	2052	2053	,
B-Characteristic	2054	2056	VD
O	2056	2057	,
O	2058	2061	and
B-Characteristic	2062	2064	FD
I-Characteristic	2065	2067	of
I-Characteristic	2068	2071	DCP
O	2072	2079	predict
B-Disease	2080	2082	DR
O	2083	2094	progression
O	2094	2095	,
O	2096	2103	whereas
B-Characteristic	2104	2106	VD
I-Characteristic	2107	2109	of
I-Characteristic	2110	2113	SCP
O	2114	2122	predicts
B-Disease	2123	2126	DME
O	2127	2138	development
O	2138	2139	.

O	2140	2143	Our
O	2144	2152	findings
O	2153	2160	provide
O	2161	2169	evidence
O	2170	2172	to
O	2173	2180	support
O	2181	2185	that
B-Diagnostic_tool	2186	2190	OCTA
O	2191	2198	metrics
O	2199	2206	improve
O	2207	2210	the
O	2211	2221	evaluation
O	2222	2224	of
O	2225	2229	risk
O	2230	2232	of
B-Disease	2233	2235	DR
O	2236	2247	progression
O	2248	2251	and
B-Disease	2252	2255	DME
O	2256	2267	development
O	2268	2274	beyond
O	2275	2286	traditional
O	2287	2291	risk
O	2292	2299	factors
O	2299	2300	.
